GlassScriptPhysician profile
Brandon Allen
NPI 1952333106
$2,445.63
in general payments reported to CMS, 2019-2025
28 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $516 · 2021: $434 · 2022: $162 · 2023: $197 · 2024: $248 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.75 | 2021-2025 | Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.67 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $201.50 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $198.90 | 2019-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $177.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $139.61 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $129.21 | 2019-2025 | |
| Amgen INC. | $126.73 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $108.57 | 2019-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Astrazeneca Pharmaceuticals LP | $107.68 | 2020-2024 | Airsupra |
| Lilly USA, LLC | $81.79 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $49.58 | 2019-2021 | |
| Allergan, INC. | $42.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $31.60 | 2019-2023 | Airduo Digihaler |
| Dynavax Technologies Corporation | $30.38 | 2024-2025 | Heplisav-B |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.08 | 2019 | |
| Inspire Medical Systems, INC. | $23.29 | 2024 | Inspire |
| Abbott Laboratories | $22.70 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $20.60 | 2019 | |
| Grifols USA, LLC | $20.56 | 2024 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $19.68 | 2021 | |
| Corium, LLC | $19.04 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $18.92 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $16.22 | 2022 | |
| Pulmonx Corporation | $15.70 | 2021 | |
| Cranial Technologies, INC | $14.70 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2020 | |
| Eisai INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.